Form 4: GeneDx CFO Kevin Feeley Reports Stock Transactions and RSU Grants

Kevin Feeley, CFO of GeneDx Holdings Corp., reports stock sales to cover tax obligations and the grant and vesting of restricted stock units (RSUs).

Summary

• Kevin Feeley, the CFO of GeneDx Holdings Corp., filed a Form 4 detailing changes in beneficial ownership.
• Feeley sold 402 shares of Class A Common Stock on March 13, 2025, at $90.0542 per share and 3,749 shares on March 17, 2025, at a weighted average price of $96.7098 per share to cover tax withholding obligations related to RSU vesting.
• He also reported the vesting of 7,197 shares on March 16, 2025.
• Feeley was granted 65,000 RSUs on March 26, 2024, which vest 25% annually starting March 26, 2025.
• An additional 15,261 RSUs were granted, vesting 25% annually starting March 15, 2026.
• Some RSUs vest in quarterly installments over a 4-year period commencing on March 16, 2023.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports routine transactions related to executive compensation. The stock sales are likely to cover tax obligations, which is a common practice.

Positives

• The vesting of RSUs indicates a long-term incentive for the CFO to remain with the company.

Negatives

• The sale of shares, even to cover tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• Continued service is required for the RSUs to vest, so any departure of the CFO would impact the unvested portion.

Future Outlook

The document outlines the vesting schedule for RSUs, indicating future equity compensation for the CFO contingent on continued service.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the actions of company executives.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotech and healthcare industries, aligning management's interests with those of shareholders.
• The vesting schedules described are fairly standard, with annual or quarterly vesting over a multi-year period.

Stakeholder Impact

• Shareholders may be interested in the CFO's transactions as an indicator of management's confidence in the company.
• The vesting of RSUs incentivizes the CFO to remain with the company, which benefits stakeholders.

Key Dates